CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

Cited by (210)

Items 201–210 of 210

1. CDK4/6 and BET inhibitors synergistically suppress pancreatic tumor growth and epithelial-to-mesenchymal transition by regulating the GSK3β-mediated Wnt/β-catenin pathway
   Jiangning Gu, Zihao Dai, Tianci Shen, Xiang 'Anthony' Chen, Zhuo Yang, Shibo Sun, Dan Chen, Haifeng Luo, Xiuli Wang, Jianqiang Xu · 2025 · Cancer Drug Resistance
2. Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights
   Cheng Xie, Jianji Ke, Feiqi Liu · 2025 · Hepatobiliary & pancreatic diseases international
3. Additional file 1 of Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma
   Xue, Zhichao, Lui, Vivian Wai Yan, Li, Yongshu, Jia, Lin, You, Chanping, Li, Xin, Wenying Piao, Yuan, Hui, Khong, Pek Lan, Kwok Wai Lo et al. · 2020 · Figshare
4. Early-Onset Pancreatic Ductal Adenocarcinoma: Clinical Features, Genomic Landscape, and Treatment-Mediated Survival Advantage
   Guoxiao Zhang, X H Shi, Huan Wang, Xiaoyi Yin, Shiwei Guo, Gang Jin · 2026 · Research Square
5. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
   Dan S. Veljovich, Michael Rothe, Elizabeth S. Garrett-Mayer, Hussein Moustapha Ali-Ahmad, Robert Wendel Naumann, Jean Siedel, John K. Chan, Andrew Gregory, Evan P. Pisick, Bamidele A. Adesunloye et al. · 2026 · JCO Precision Oncology
6. CDK4/6-related inhibitors from a medicinal chemistry perspective: Research advances in the past six years (2020–2025)
   Cunqin Wang, Yanhua Zhang, Shuyun Bao, Xiaojun Huang, Cheng Wang, Yonglei Zhang · 2026 · Bioorganic Chemistry
7. Targeting the untargeted: Emerging targeted therapies in metastatic melanoma beyond BRAF/MEK inhibitors
   M.-E. Dimitrakopoulou, Charalampos Theocharopoulos, Aikaterini Katsandri, Dimitra Foteinou, Dimitra T. Stefanou, Aikaterini Gkoufa, Konstantinos Tsoukalas, Thalia Bousou, Amalia N. Anastasopoulou, Helen Gogas et al. · 2026 · Critical Reviews in Oncology/Hematology
8. BindingDB Entry 50002926: Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
   BindingDB · 2020 · UC San Diego
9. BindingDB Entry 50006187: Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a nonplanar analogue of fascaplysin, inhibits Cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity.
   BindingDB · 2020 · UC San Diego
10. BindingDB Entry 50007798: Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.
    BindingDB · 2021 · UC San Diego